CareLit Fachartikel

Preclinical evaluation of the PARP-inhibitor olaparib for the treatment of ovarian clear cell cancer

KJ Dedes, P Wilkerson, D Wetterskog, MB Lambros, R Natrajan, D Tan, CJ Lord, SB Kaye, A Ashworth, JS Reis-Filho · Geburtshilfe und Frauenheilkunde · 2011 · Heft 08

Dokument
867042
CareLit-ID
Jahr
2011
Publikation
PDF
nein
Metadaten
DOI
ja
zitierfähig

Bibliografische Angaben

Zeitschrift
Geburtshilfe und Frauenheilkunde
Autor:innen
KJ Dedes, P Wilkerson, D Wetterskog, MB Lambros, R Natrajan, D Tan, CJ Lord, SB Kaye, A Ashworth, JS Reis-Filho
Ausgabe
Heft 08 / 2011
Seiten
–
Erschienen: 2011-08-30 00:00:00
ISSN
0016-5751
DOI
10.1055/s-0031-1286501

Zusammenfassung

Fragestellung: Ovarian clear cell carcinoma (OCCC) is an aggressive histological subtype of epithelial ovarian cancer. De-novo resistance to platinum-based chemotherapy is higher compared to serous ovarian cancers. The aims of this study were to examine the role of a potent poly(ADP) ribose polymerase (PARP)-inhibitor as a potential therapeutic option for OCCCs and if RAD51 foci formation would constitute a surrogate marker for the use of these agents in OCCCs. Methode: Twelve OCCC cell lines were tested for their ability to elicit phospho-γ-H2AX foci (a marker of induction of DNA damage) and RAD51 foci (a marke…

Schlagworte

Cisplatin ADP-Ribose Geburtshilfe und Frauenheilkunde